NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

August 29, 2026

Conditions

Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular LymphomaLymphoma, Non-HodgkinMantle Cell LymphomaBladder CancerUveal Melanoma, RecurrentCervix CancerCarcinoma in SituHead and Neck Squamous Cell CarcinomaSkin CancerMetastatic CancerTumor, SolidTumor Recurrence

Interventions

DRUG

ONM-501

Intratumoral injection

DRUG

Cemiplimab

Intravenous administration of 350 mg

Trial Locations (15)

2010

RECRUITING

St Vincent's Hospital, Darlinghurst

2500

RECRUITING

Cancer Care Wollongong, Wollongong

4215

RECRUITING

Tasman Oncology Research, Southport

4556

RECRUITING

University of the Sunshine Coast Clinical Trials, Buderim

6008

ACTIVE_NOT_RECRUITING

St John of God Subiaco Hospital, Subiaco

15224

RECRUITING

Allegheny Health Network, Pittsburgh

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

22031

RECRUITING

Virginia Cancer Specialists, PC, Fairfax

33321

WITHDRAWN

BRCR Global, Tamarac

43210

RECRUITING

Ohio State University, Columbus

44718

RECRUITING

Gabrail Cancer Center Research, Canton

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

90027

RECRUITING

California Research Institute, Los Angeles

Unknown

RECRUITING

Southern Oncology Clinical Research Unit, Bedford Park